We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genus Plc | LSE:GNS | London | Ordinary Share | GB0002074580 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.00 | 0.50% | 1,796.00 | 1,796.00 | 1,810.00 | 1,799.00 | 1,796.00 | 1,796.00 | 2,078 | 09:31:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 689.7M | 33.3M | 0.5043 | 35.44 | 1.18B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/2/2024 07:23 | Well I think its good I sold this. I don't understand how management always say they are inline with expectations, but some how profit is forecast to fall almost 20%. Anyways 30x pe now. In this market bargains are to be had... and this ain't cheap enough. | mortal1ty | |
03/11/2023 12:53 | Think you are a bit optimistic there! I would say $100m with 90% margins five years out is about right for the US. This could easily be the same for China and throw in ROW and you might be near your figure. All in this could justify a tripling of the share price imho 2 to 3 years out once they start to ramp. | edwardt | |
02/11/2023 20:48 | Just had a look at the capital markets day presentation. 6.1m sows in the US. $3 to $4 per month extra for the sows that are prrsv resistant. That's an extra 300m usd in revenue with high drop through. Ramping up to that over 5 years. Nice! | mortal1ty | |
02/11/2023 20:22 | In my opinion this business will be taken out at c. 40. Some private equity company will see the opportunity and quality of this business. Its still down 60% from its peak. They can pay 40 and secure the deal. Then benefit from the last 5 years of development that is coming through. | mortal1ty | |
02/11/2023 20:16 | In my opinion this business will be taken out at c. 40. Some private equity company will see the opportunity and quality of this business. Its still down 60% from its peak. They can pay 40 and secure the deal. Then benefit from the last 5 years of development that is coming through. | mortal1ty | |
02/11/2023 11:42 | finally waking up to the enormity of the disease resistant pigs opportunity? it literally could be HUGE imo. not sure i can think of a uk listed company with such a game changer solution to a very expensive problem. | edwardt | |
11/10/2023 09:23 | Legging back in starting @ 22Decent update and long term v interesting prospects across the globeChina gov has been in the market stockpiling and boosted pork price by 25pc since JulyOne way bet from here | the white house | |
10/10/2023 13:20 | Completely missed this announcement. Good news. Expecting the shares to start moving up as speculators play the news flow coming through in H1. This business is one of the cheapest out there, given in quality, market position and pipeline. | mortal1ty | |
05/10/2023 19:50 | Hopefully that was the first of many approvals. The extent of the problem is eye catching. 15% cost saving on that would mean we make a truck load of cash | edwardt | |
18/7/2023 12:57 | Not so fast. Let's see when they announce on their disease resistant pigs. The share price will fly... | edwardt | |
17/5/2023 13:37 | Back to £20 | elliotset | |
07/12/2022 10:57 | Pork high & china easing Legged in again @ 30One way | the white house | |
17/11/2022 16:09 | China Pork prices still running 20pc higher than noted in interim in SeptOne way bet with China moving Added at 30 | the white house | |
10/10/2022 07:54 | ft leads with article on soaring pork prices in china | edwardt | |
13/9/2022 20:46 | I was interested to read Citywire's take of the recent Peel Hunt note quote Peel Hunt upgrades underappreciated Genus Peel Hunt has upgraded Genus (GNS), which manufactures biotech and genetics products for cattle and pig farmers, after saying it is ‘back on the front foot’. Analyst Charles Hall upgraded his recommendation from ‘hold’ to ‘buy’ but retained his target price of £45 on the stock, which shot up 16.7% to close at £27.98 on Thursday after a trading update. Full-year 2022 was a challenging year for the group, with sharp declines in its China business as pork prices slumped, combining with pressure on producers from soaring input costs. ‘The outlook in China porcine now looks more encouraging, helped by the reduction in the sow herd and rising hog prices,’ said Hall. ‘Furthermore, commodity prices are adjusting to reflect the higher input costs.’ Despite ‘strong underlying performance, improved visibility in China, and currency benefit’, the shares have ‘materially derated and there is effectively nothing in the valuation for the significant potential in gene editing, which is on track for commercialisation in full-year 2024’. Hall added ‘there is little doubt of the direction of travel for revenue prospects’ and there is ‘good cost management in place against the inflationary backdrop’. unquote | cerrito | |
28/7/2022 16:48 | News due on disease resistant pigs? Suddenly caught a bid... | edwardt | |
30/5/2022 08:07 | Shanghai lockdowns ending Wednesday, lowest number of Covid in 3 monthscontinue to add on favourable news and drift up | the white house | |
20/5/2022 09:56 | Can you expand, the white house please, on what China news you are referring to. Thanks | cerrito | |
20/5/2022 07:46 | China news helpingadding as we rise given substantial US progress noted | the white house | |
11/5/2022 11:08 | Out @ 50back in high 23What could go wrong' | the white house | |
10/2/2022 16:54 | Interesting company. Does anyone know if there's any broker research available? | epistrophy | |
29/9/2021 09:25 | Gotta LOVE the very strong performance etc headline, In CAPITALS, in the results, 5 days before the 2 main players shift 1 million pounds worth each | the white house | |
29/9/2021 07:41 | Uk to allow gene edited pigs by year end. | edwardt | |
09/9/2021 12:03 | Blip in road for 22. I still see a mountain of opportunities here | edwardt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions